GlassScriptPhysician profile
Suzanne Ferree Turner
NPI 1023045663
$6,931.52
in general payments reported to CMS, 2019-2025
32 companies · $579 in 2025
The $579 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $1,238 · 2021: $1,437 · 2022: $1,341 · 2023: $694 · 2024: $689 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,962.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,809.52 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $934.67 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $776.63 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $666.89 | 2019-2025 | Octrode, Proclaim |
| Pfizer INC. | $407.89 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $222.31 | 2019-2023 | Breztri |
| Allergan, INC. | $217.07 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $210.69 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.97 | 2019-2025 | Xifaxan |
| Ibsa Pharma INC. | $175.61 | 2019-2022 | |
| Amgen INC. | $145.68 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $132.18 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $108.97 | 2022 | |
| Glaxosmithkline, LLC. | $101.30 | 2020-2022 | |
| Eisai INC. | $98.88 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $80.87 | 2019-2023 | Belsomra |
| Romark Laboratories, Lc | $80.59 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $78.49 | 2019 | |
| Kvk-Tech, INC. | $75.15 | 2019 | |
| Astellas Pharma US INC | $74.67 | 2019-2025 | Veozah |
| Biohaven Pharmaceuticals, INC. | $60.69 | 2021 | |
| Daiichi Sankyo INC. | $60.37 | 2021-2022 | |
| Exact Sciences Corporation | $49.88 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $25.91 | 2019 | |
| Esperion Therapeutics, INC. | $25.86 | 2021 | |
| Genentech USA, INC. | $23.36 | 2020 | |
| Sanofi Pasteur INC. | $17.33 | 2019 | |
| Linus Health, INC. | $16.23 | 2022 | |
| Therapeuticsmd, INC. | $15.07 | 2019 | |
| Concordia Pharmaceuticals INC. | $14.55 | 2019 | |
| Currax Pharmaceuticals LLC | $14.46 | 2021 | |
| Jazz Pharmaceuticals INC. | $11.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.